LP
WST icon

LGL Partners’s West Pharmaceutical WST Stock Holding History

LGL Partners’s Portfolio WST Stock Details WST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$374K Buy
1,041
+1
+0.1% +$306 0.14% 46
2026
Q1 		$261K Buy
1,040
+1
+0.1% +$249 0.11% 56
2025
Q4 		$286K Buy
1,039
+1
+0.1% +$274 0.12% 45
2025
Q3 		$272K Hold
1,038
– – 0.12% 46
2025
Q2 		$250K Buy
1,038
+2
+0.2% +$428 0.11% 48
2025
Q1 		$232K Buy
1,036
+385
+59% +$106K 0.11% 49
2024
Q4 		$213K Buy
+651
New +$205K 0.03% 113

Other funds holding WST

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
GIM
Generation Investment Management London, United Kingdom $10.3B AUM 4.84% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

LGL Partners's WST Position: Q2 2026 in Review

LGL Partners increased its West Pharmaceutical (WST) stake by 0.1% in Q2 2026, buying an estimated $306 and bringing the position to 1,041 shares worth $374K. The position accounts for 0.14% of the portfolio, ranked #46.

LGL Partners first reported a position in WST in Q4 2024 and has held it in 7 quarters since. 831 funds tracked by Wall St. Rank hold WST as of Q2 2026.

  • LGL Partners held 1,041 shares of West Pharmaceutical worth $374K as of Q2 2026.
  • LGL Partners bought 1 West Pharmaceutical share in Q2 2026, an estimated $306.
  • West Pharmaceutical made up 0.14% of LGL Partners's portfolio in Q2 2026, its #46 holding.
  • LGL Partners first reported a position in West Pharmaceutical in Q4 2024 and has held it in 7 quarters since.
  • 831 funds tracked by Wall St. Rank held West Pharmaceutical as of Q2 2026.

Based on LGL Partners's 13F filing for Q2 2026, filed 27 Jul 2026.